GlassScriptPhysician profile
Vincent Wong
NPI 1851611487
$7,371.84
in general payments reported to CMS, 2019-2025
34 companies · $747 in 2025
The $747 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,689 · 2020: $363 · 2021: $547 · 2022: $1,294 · 2023: $1,231 · 2024: $1,500 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $948.20 | 2019-2024 | Farxiga, Wainua |
| Boston Scientific Corporation | $772.72 | 2019-2024 | Rezum Generator, Spaceoar Vue System - 10ml |
| Novartis Pharmaceuticals Corporation | $749.43 | 2019-2025 | |
| Pfizer INC. | $607.70 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $588.11 | 2019-2024 | Camzyos, Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.62 | 2019-2024 | Jardiance |
| Amgen INC. | $336.96 | 2019-2024 | Repatha |
| Abiomed | $251.32 | 2021-2024 | Impella |
| Abbvie INC. | $244.40 | 2025 | |
| Artivion, INC. | $237.25 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.77 | 2019-2024 | Lifevest |
| Astellas Pharma US INC | $189.94 | 2019 | |
| Heartflow, INC. | $183.60 | 2024-2025 | |
| Cleerly, INC. | $148.59 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Siemens Medical Solutions USA, INC. | $144.92 | 2025 | Magnetom Sola |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $144.44 | 2019-2023 | Amvuttra |
| Merck Sharp & Dohme LLC | $143.90 | 2023-2025 | Verquvo, Bridion, Winrevair |
| Janssen Pharmaceuticals, INC | $142.31 | 2019-2024 | Xarelto |
| W. L. Gore & Associates, INC. | $138.24 | 2024 | Gore Cardioform Septal Occluder |
| Regeneron Healthcare Solutions, INC. | $137.64 | 2019 | |
| Cvrx, INC. | $134.34 | 2022 | |
| Medtronic Vascular, INC. | $123.94 | 2019 | |
| Olympus America INC. | $110.84 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $49.25 | 2020-2024 | Uptravi |
| Abbott Laboratories | $39.60 | 2023 | Cardiomems, Coroflow |
| Medtronic, INC. | $26.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.03 | 2024 | Xifaxan |
| Ardelyx, INC. | $23.87 | 2023 | Ibsrela |
| Lantheus Medical Imaging, INC. | $23.66 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.15 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $18.27 | 2024 | |
| Terumo Medical Corporation | $17.64 | 2019 | |
| Ge Healthcare | $16.33 | 2024 | |
| Gilead Sciences, INC. | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.